SPC
TEVA icon

Slate Path Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Slate Path Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,927,998
Closed -$160M – 61
2025
Q3 		$160M Sell
7,927,998
-362,000
-4% -$6.36M 2.48% 15
2025
Q2 		$139M Sell
8,289,998
-1,366,000
-14% -$22M 2.4% 17
2025
Q1 		$148M Buy
9,655,998
+1,164,965
+14% +$20.8M 2.68% 14
2024
Q4 		$187M Sell
8,491,033
-5,177,200
-38% -$94.2M 3.38% 9
2024
Q3 		$246M Sell
13,668,233
-6,522,951
-32% -$114M 3.79% 5
2024
Q2 		$328M Sell
20,191,184
-6,705,000
-25% -$103M 6.25% 1
2024
Q1 		$380M Buy
26,896,184
+665,000
+3% +$8.38M 7.52% 1
2023
Q4 		$274M Buy
26,231,184
+2,387,184
+10% +$22.3M 6.08% 2
2023
Q3 		$243M Buy
23,844,000
+11,407,000
+92% +$106M 6.78% 2
2023
Q2 		$93.7M Buy
+12,437,000
New +$101M 3.42% 12

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Slate Path Capital's TEVA Position: Q4 2025 in Review

Slate Path Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 7,927,998 shares — an estimated $160M sold.

Slate Path Capital first reported a position in TEVA in Q2 2023 and held it in 10 quarters. The position peaked at $380M in Q1 2024. 630 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Slate Path Capital reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Slate Path Capital sold 7,927,998 Teva Pharmaceuticals shares in Q4 2025, an estimated $160M.
  • Slate Path Capital first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 10 quarters.
  • Slate Path Capital's Teva Pharmaceuticals position peaked at $380M in Q1 2024.
  • 630 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Slate Path Capital's 13F filing for Q4 2025, filed 17 Feb 2026.